Fig. 1.Effect of olokizumab on blood cell phenotypes in COVID-19
patients.
I. Platelets. Mostly discs in controls (A); less
quantity, activation, sphere transformation, at COVID-19 admission (B);
Olokizumab effect on platelets is dependent on enoxaparin dose. Daily enoxaparin
4000 IU on top of Mab cause no effect, but enoxaparin 8000 IU + olokizumab
decrease platelet activation (E) more than basic therapy without MAb (F). Arrows
indicate normal discoid platelets (*) and activated spherical platelets (⁑).
Magnification 10,000 for all cell images.
II. Leukocytes. No clusters or neutrophil extracellular traps in
controls (G); massive traps in COVID admission samples exhibited by
N-arrows (H); less or no traps after olokizumab (J), and more traps without Mab
(K). Arrows indicate single neutrophils () and
neutrophil extracellular traps (). Magnification 10,000 for all cell images.
III. Erythrocytes. Biconcave shape with no rouleaux formation in
controls (L); transformation of erythrocytes into echinocytes (M); less
echinocytes in numbers and piles after olokizumab (N) and less changes on basic
therapy (O). Arrows indicate normal biconcave erythrocytes (֍) and echinocytes
(⁂). Magnification 5000 for all cell images.